电话:
400-7060-959
传真:
+86 10 56315212-8813
电子邮件:
orders@antibodies-online.cn

Recombinant TNF alpha (Adalimumab Biosimilar) 抗体

适用: 人 FACS, in vivo 宿主: 小鼠 Monoclonal D2E7 unconjugated Recombinant Antibody
产品编号 ABIN7200655
发货至: 中国
  • 抗原 See all TNF alpha (Adalimumab Biosimilar) products
    TNF alpha (Adalimumab Biosimilar)
    抗体类型
    Recombinant Antibody
    适用
    宿主
    • 2
    • 2
    • 1
    • 1
    • 1
    小鼠
    克隆类型
    • 7
    单克隆
    标记
    • 7
    This TNF alpha (Adalimumab Biosimilar) antibody is un-conjugated
    应用范围
    • 6
    • 5
    • 5
    • 3
    • 2
    • 1
    Flow Cytometry (FACS), In vivo Studies (in vivo)
    原理
    Adalimumab Biosimilar, TNF alpha Monoclonal Antibody
    特异性
    The monoclonal antibody adalimumab biosimilar specifically binds to the human TNF alpha.
    产品特性
    Recombinant Humanized IgG1 Monoclonal Antibody.
    纯化方法
    Protein A affinity column
    纯度
    > 95% by SDS-PAGE under reducing conditions and HPLC.
    过滤
    0.2 μm filtered
    内毒素水平
    < 1 EU per 1 mg of the protein by the LAL method.
    免疫原
    The monoclonal antibody adalimumab biosimilar was produced in the adalimumab biosimilar CHO stable cell line.
    克隆位点
    D2E7
    亚型
    IgG1 kappa
  • 应用备注
    ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by adalimumab.
    限制
    仅限研究用
  • 状态
    Liquid
    浓度
    1 mg/mL
    缓冲液
    PBS, pH 7.4, no stabilizers or preservatives.
    储存液
    Without preservative
    注意事项
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    储存条件
    -20 °C
    储存方法
    12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
    有效期
    12 months
  • 抗原
    TNF alpha (Adalimumab Biosimilar)
    Abstract
    TNF alpha (Adalimumab Biosimilar) 产品
    别名
    DIF antibody, TNF-alpha antibody, TNFA antibody, TNFSF2 antibody, tumor necrosis factor antibody, TNF antibody
    物质类
    Biosimilar
    背景
    Adalimumab, the first fully human monoclonal antibody drug approved by FDA, binds to TNFα, inactivates TNF receptors, and downregulates the inflammatory reactions associated with a variety of autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis and juvenile idiopathic arthritis.

    Mainly produced by activated macrophages (M1), Tumor necrosis factor (TNF, cachexin, cachectin, tumor necrosis factor alpha, TNFα) plays important roles in the regulation of immune cells. As a member of a group of cytokines that stimulate the acute phase reaction, TNF is involved in systemic inflammation and able to induce fever, apoptotic cell death, cachexia, inflammation, and to inhibit tumorigenesis and viral replication and respond to sepsis via IL1 & IL6 producing cells. Dysregulation of TNF expression could have serious impact in a variety of human diseases including Alzheimer's disease, cancer, major depression and inflammatory bowel disease.
You are here: